TrialBlood2019

Ibrutinib plus lenalidomide and rituximab has promising activity in relapsed/refractory non-germinal center B-cell-like DLBCL.

Andre Goy et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.